Could FDA And CDC’s COVID-19 Vaccine AdComs Be Better Coordinated? FDA’s Marks Thinks So
Executive Summary
Federal government needs to make sure its messaging on vaccines is harmonized, CBER director Marks says. Vaccine development could have been accelerated in pregnant, pediatric and immunocompromised populations, he notes.
You may also be interested in...
CMS Needs Regulatory Science, Chief Scientist To Coordinate With US FDA, Former Official Says
Sean Tunis embraces a bigger decision-making role for CMS in product access, while FDA Commissioner nominee Robert Califf also calls for smoother FDA-CMS hand-offs, and CBER Director Peter Marks wants a quicker FDA-CDC approval and deployment process.
US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says
Instead of waiting until after regulatory events like COVID boosters and Aduhelm, FDA should describe its decision-making process along the way to help restore public faith in the agency, former deputy commissioner Josh Sharfstein says.
US FDA’s Woodcock ‘Managing As If She’s Been Commissioner,’ Not Afraid To Act, CBER Director Says
Peter Marks says Acting Commissioner Janet Woodcock’s tenure running the FDA has been no different than if a permanent commissioner were in place.